TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01490255

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranolazine
Description: os, 750 mg, twice per day, for 15 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: os, 10 mg, once daily, 15 days
Study: NCT01091168

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alkylating agent of physician choice registered in cancer
Description: cyclophosphamide or melphalan or mitomycin C or thiotepa or cisplatin or carboplatin
Study: NCT03333018

Intervention type: DRUG
Intervention: Aclidinium bromide
Description: Administered as monotherapy, prescribed as recorded in the database.

Intervention type: DRUG
Intervention: Aclidinium bromide/formoterol
Description: Administered in combination with formoterol fumarate (concomitant or as a fixed-dose combination), prescribed as recorded in the database.

Intervention type: DRUG
Intervention: Other COPD medication
Description: Other COPD medication including:~tiotropium; other long-acting anticholinergic (LAMAs; lycopyrronium bromide, umeclidinium); LABA (formoterol, salmeterol, indacaterol); LABA/ICS (formoterol/budesonide, formoterol/beclometasone, formoterol/mometasone, formoterol/fluticasone, salmeterol/fluticasone propionate, and vilanterol/fluticasone); LAMA/LABA (approved or under regulatory review or in development; glycopyrrolate/formoterol, glycopyrronium/indacaterol, tiotropium/olodaterol, umeclidinium/vilanterol), prescribed as recorded in the database.
Study: NCT02261649

Intervention type: DEVICE
Intervention: Medoc Advanced Medical Systems PATHWAY Model ATS
Description: 30 minutes of sensory testing using a contact thermal stimulator will measure thresholds for heat and cool detection, and threshold for hot and cold pain.

Intervention type: DEVICE
Intervention: Medoc Advanced Medical Systems PATHWAY Model ATS
Description: 30 minutes of sensory testing using a contact thermal stimulator will measure thresholds for heat and cool detection, and threshold for hot and cold pain.

Intervention type: PROCEDURE
Intervention: Cold water bath
Description: The next 15 minutes of sensory testing will measure tolerance to having right or left hand in a tub of cold water. The participant will place their hand in cold water and leave it there for as long they can, even if it is uncomfortable. The participant can take their arm out if it gets too uncomfortable to leave it in.

Intervention type: PROCEDURE
Intervention: Cold water bath
Description: The next 15 minutes of sensory testing will measure tolerance to having right or left hand in a tub of cold water. The participant will place their hand in cold water and leave it there for as long they can, even if it is uncomfortable. The participant can take their arm out if it gets too uncomfortable to leave it in.

Intervention type: DEVICE
Intervention: MRI scanner
Description: An MRI will be used to collect anatomical and functional images from patients and subjects. These data will be collected within a 1 hour block.
Study: NCT04907422

Intervention type: DIAGNOSTIC_TEST
Intervention: CD24-Gold Nanocomposite expression using Real-time quantitative polymerase chain reaction
Description: new strategy where gold nanoparticles synthetized and added to CD24 primer forming CD24-Gold Nanocomposite to be used for detection of cancer stem cells

Intervention type: DIAGNOSTIC_TEST
Intervention: CD24-Gold Nanocomposite expression using Real-time quantitative polymerase chain reaction
Description: new strategy where gold nanoparticles synthetized and added to CD24 primer forming CD24-Gold Nanocomposite to be used for detection of cancer stem cells
Study: NCT03338400

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Patients will be randomized to Dexamethasone arm will receive 8mg (2ml) of Dexamethasone at the time of induction.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Patients randomized to normal saline will receive 2ml of Normal saline at the time of induction.
Study: NCT03345511

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Guided Caudal Block
Description: Using an external ultrasound probe, the investigators guided a 18 gauge epidural needle into the caudal space and injected a local anesthetic solution consisting in bupivacaine 0.25%, lidocaine 1% and dexamethasone 8mg in the caudal space.
Study: NCT03972618

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Installation of water filtration system for filtering existing water source
Description: Installation of water filtration system and education on hand washing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Installation of water filtration system for filtering existing water source
Description: Installation of water filtration system and education on hand washing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Installation of water filtration system for filtering existing water source
Description: Installation of water filtration system and education on hand washing.
Study: NCT04310696

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Buteyko Breathing exercises
Description: Buteyko breathing technique was performed by asking the patient to take a small breath in and then out and hold his/her breath and count the time in seconds, as long as he or she can, until first signs of air hunger start to appear, followed by normal breathing once again. This procedure was repeated 15 times, three sets of 15 repetitions were given to the patient per day, 3 days per week and the treatment was continued for 4 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pursed lip breathing
Description: Pursed lip breathing was performed as nasal inspiration followed by expiratory blowing against partially closed lips. Participants received a total of 3 sets of 15 repetitions per day, 3 times a week and the treatment was continued for 4 weeks.
Study: NCT02681653

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin or placebo given for 7 days to patients of septic shock admitted to ICU

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Equally matched placebo for 7 days to patients of septic shock admitted to ICU
Study: NCT00752492

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Isocapnic Hyperpnoea
Description: IH is a method of increasing alveolar ventilation (Va) while preventing the unwanted hypocapnia by addition of CO2 to the inhaled mixture.
Study: NCT05001971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Plus Penpulimab
Description: Anlotinib: 10mg orally daily on day 1 to 14 of a 21-day cycle. Penpulimab: 200mg by intravenous drip on day 1 of a 21-day cycle.
Study: NCT01803971

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Obtention of vascular access in out-of-hospital cardiac arrest patients according to the current strategy
Description: Current strategy of obtention of a vascular access : first attempt by peripheral venous access and if failure switch to intraosseous route
Study: NCT02078752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06647263
Description: Part 1- PF-06647263 will be administered intravenously in either a 21 day cycle or weekly in cohorts of 2 or more patients starting at a dose of 0.015 mg/kg. Increases in dose will continue until MTD is determined.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06647263
Description: Part 2- Patients with triple negative breast cancer will be treated at the MTD or Recommended Phase 2 dose selected in Part 1.
Study: NCT05524077

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ablation
Description: Catheter ablation (CA) will be performed in the standard fashion (described in international guidelines for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death from the AHA/ACC/HRS and the expert consensus statement on Catheter Ablation of Ventricular Arrhythmias from HRS/EHRA/APHRS/LAHRS). CA will be performed under conscious sedation or GA by an Electrophysiologist trained in cardiac arrhythmia ablation. CA will be guided by a combination of mapping techniques (standard practice), and described in guidelines for CA for VT. Mapping techniques will include pace, entrainment, activation, and electro-anatomic substrate mapping, where haemodynamically tolerated. Expected procedure duration is 3-6hrs.~Post-CA, AAD is stopped if patient was drug naïve pre-randomisation. The baseline type/dose of AAD pre-randomisation is continued if the patient was on an AAD pre-randomisation. Repeat ablations are permitted within 30-days post-randomisation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-arrhythmic Drugs (AADs)
Description: Standard care usually encompasses patients who have not previously had AADs, being commenced on sotalol 80mg twice/day. Lower doses may be initiated by treating doctor, as clinically indicated. If there is contraindication to sotalol, another beta-blocker may be initiated using standard doses. Clinicians may consider alternative AADs if there is contraindication to beta-blockers. Doses would be up titrated to the maximal tolerated amount.~For patients already on an AAD, amiodarone would usually be added, as per VANISH trial.~They will receive a loading dose 400mg twice/day for 2 weeks, followed by 400mg/day for 4 weeks and 200mg/day thereafter. Patients who have failed amiodarone dose \<300mg/day will receive a repeat loading dose of 400mg twice/day for 2 weeks, followed by 400mg/day for 1 week, and 300mg/day thereafter.~If the treating doctor decides to do a CA for VT, the occurrence and timepoint of cross-over will be recorded. Cross-over is estimated to be \<2% (VANISH trial).
Study: NCT01563900

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auto-titration CPAP
Description: An auto-titration CPAP will be set at a pressure between 5 to 15 cwp. This device delivers pressure as needed by the patient at any given time while using the device.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-CPAP
Description: The sham-CPAP device will be set at 4 centimeters of water pressure (cwp). An exhalation connector will be place between the mask interface and the tubing without the enlarged port to maintain blinding; the final pressure delivered to the participant will be 2 cwp.
Study: NCT03569033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant
Description: Gefapixant 45 mg will be administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet matching gefapixant will be administered orally.
Study: NCT02261649

Intervention type: DEVICE
Intervention: MRI scanner
Description: An MRI will be used to collect anatomical and functional images from patients and subjects. These data will be collected within a 1 hour block.

Intervention type: OTHER
Intervention: Questionnaires
Description: The surveys include questions about emotions, thoughts, and feelings. These surveys will be given before sensory testing and before the MRI scan. The parent or guardian will help to complete two surveys, and will complete one survey on his or her own. Questions can be skipped, and may be stopped at any time.

Intervention type: OTHER
Intervention: Questionnaires
Description: The surveys include questions about emotions, thoughts, and feelings. These surveys will be given before sensory testing and before the MRI scan. The parent or guardian will help to complete two surveys, and will complete one survey on his or her own. Questions can be skipped, and may be stopped at any time.
Study: NCT01893970

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SWIFT
Description: Participants will receive: 1) acute social work intervention for adults with mTBI, including early education, reassurance, resources and brief alcohol intervention in the ED (SWIFT-Acute) and 2) follow up telephone counseling, needs assessment and case management referral to necessary services (SWIFT).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SWIFT-Acute
Description: acute social work intervention for adults with mTBI, including early education, reassurance, resources and brief alcohol intervention in the ED (SWIFT-Acute)
Study: NCT01260870

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cotavance Paclitaxel Coated Balloon

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard balloon angioplasty
Study: NCT01388777

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visica 2™ Treatment System
Description: The Visica 2™ Treatment System uses a closed system to circulate liquid nitrogen within the probe tip creating sub-freezing temperatures that result in precision cryoablation of the intended target tissue.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: Cryoablation procedure uses a hollow, thin tube called a cryoprobe to freeze and destroy cancer tissue. The cryoprobe needle insertion is done using ultrasound guide to reach target, procedure lasts about 20 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Resection
Description: Complete surgical resection of the primary tumor following cryoablation therapy.
Study: NCT03859869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pancrelipase
Description: Pancrelipase is administered orally as capsules with a meal or snack

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pancrelipase
Description: Pancrelipase is administered orally as capsules with a meal or snack

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pancrelipase
Description: Pancrelipase is administered orally as capsules with a meal or snack

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is administered orally as capsules with a meal or snack

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is administered orally as capsules with a meal or snack
Study: NCT03448510

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation
Description: The subject will receive Irreversible electroporation procedure which is a novel ablation modality using electric pulses to create nanoscale defects in the cell membrane.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medication
Description: The subject will be prescribed with α-blocker or/and 5α-reductase inhibitors.
Study: NCT03640949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressin, Arginine
Description: 20 IE of vasopressin per dose for a maximum of four doses (80 IU)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: 40 mg methylprednisolone once

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl
Description: Placebo
Study: NCT03608202

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: POCUS protocol group
Description: The findings of multiorgan ultrasound can modify diagnoses and treatments and immediate interventions (eg volume loading with saline solution, pleural or pericardial drainage, initiation of diuretics, increase in positive end expiratory pressure, etc.).~This protocol is performed in the first 24 h of admission to the Intensive Care Unit (ICU) and is repeated at 24 h.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Routine protocol of the treating team is followed
Study: NCT02740283

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: glycemic monitoring

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary guide
Study: NCT00761553

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary supplements with exercise
Description: Resistive exercise along with consuming two dietary supplements every day during both 8 week intervention periods, for a total of 16 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary supplements with exercise
Description: Resistive exercise along with consuming two dietary supplements every day during both 8 week intervention periods, for a total of 16 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary supplement without exercise
Description: Consuming two dietary supplements every day during both 8 week intervention periods, for a total of 16 weeks.
Study: NCT04907422

Intervention type: DIAGNOSTIC_TEST
Intervention: CD24-Gold Nanocomposite expression using Real-time quantitative polymerase chain reaction
Description: new strategy where gold nanoparticles synthetized and added to CD24 primer forming CD24-Gold Nanocomposite to be used for detection of cancer stem cells

Intervention type: DIAGNOSTIC_TEST
Intervention: non-conjugated CD24 expression using Real-time quantitative polymerase chain reaction
Description: conventional strategy using non-conjugated CD24 expression to used for detection of cancer stem cells

Intervention type: DIAGNOSTIC_TEST
Intervention: non-conjugated CD24 expression using Real-time quantitative polymerase chain reaction
Description: conventional strategy using non-conjugated CD24 expression to used for detection of cancer stem cells

Intervention type: DIAGNOSTIC_TEST
Intervention: non-conjugated CD24 expression using Real-time quantitative polymerase chain reaction
Description: conventional strategy using non-conjugated CD24 expression to used for detection of cancer stem cells
Study: NCT04443296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCRT+TIL
Description: Cisplatin based chemotherapy concurrently with radiotherapy, then TIL infusing following concurrent chemoradiotherapy
Study: NCT01135017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronedarone
Description: Film-coated tablet~Oral administration under fed conditions (during breakfast and dinner)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Dronedarone)
Description: Film-coated tablet strictly identical in appearance~Oral administration under fed conditions (during breakfast and dinner)
Study: NCT00149383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02268071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment will be stopped for 1 year unless hypertension recurrence
Description: For patients with average of HBPM values \<135/85mmHg at baseline, the antihypertensive treatment will be stopped for 1 year (half dose for 3 days then interruption)
Study: NCT04394143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD128
Description: Oral administration of two capsules before sleep for 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mannitol
Description: Oral administration of two capsules before sleep for 7 days.
Study: NCT03124901

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DCI pulse oximeter sensor
Study: NCT02585076

Intervention type: OTHER
Intervention: Standard of care
Description: As prescribed by treated physician
Study: NCT05565014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Virus Activated Killer immune Cells
Description: The VAK made from Pleural Effusion should be given to treat Malignant Pleural Effusion.The VAK made from Peritoneal Effusion should be given to treat Malignant Peritoneal Effusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: The use of saline was the same as VAK group.
Study: NCT00688545

Intervention type: DRUG
Intervention: Celecoxib
Description: Non-interventional: Treatment assignment as per treating physician's judgement

Intervention type: DRUG
Intervention: nsNSAIDs
Description: Non-interventional: Treatment assignment as per treating physician's judgement
Study: NCT02740218

Intervention type: OTHER
Intervention: Patient questionnaire
Description: Patients will be asked to complete a questionnaire regarding their expectations, experience and satisfaction in taking OTEZLA (apremilast) treatment
Study: NCT03527771

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Video-assisted CPR
Description: Emergency call using a Software capable of video Transmission for Video assistance in CPR

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: telephone-assisted CPR
Description: Emergency call with telephone assistance in CPR
Study: NCT03351010

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness training program
Description: The mindfulness training program is a self-awareness mindfulness training program by performing the 15-position hand movement series

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cancer pain educational program
Description: A cancer pain education program by using Videos and personalized face-to-face techniques

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cancer pain educational program
Description: A cancer pain education program by using Videos and personalized face-to-face techniques
Study: NCT01457924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab 3mg
Description: 3mg of investigational product
Study: NCT04461561

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: end-of-life nursing education consortium-pediatric palliative care as web based-training plus usual care
Description: The End-of-Life Nursing Education Consortium (ELNEC) project is a national education initiative to improve nursing education on end-of-life care. The project is administered by the American Association of Colleges of Nursing and City of Hope National Medical Center. The intervention group received training through the Relais Academy website
Study: NCT00998478

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Activity Knowledge Circuits
Description: The activity knowledge circuits were implemented, where in addition to regular physical education (PE) activity was increased by two hours a week over an 18-week period. Participants briskly walked 3200 m twice weekly during curriculum lessons (60 min). Short tasks, in line with current curriculum, were provided by subject teachers for participants to complete at stations set every 400 or 800 m. Crucially participants continued to follow national curriculum whilst exercising. Tasks designed by teachers lasted no longer than 60 seconds at each station. With the exception of PE, each curriculum subject delivered a total of four intervention lessons. Circuits were performed outdoors on school premises, with an indoor course of equal distance used during adverse weather conditions.
Study: NCT02953470

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual tailored functional exercise
Description: Receive individual tailored exercise to increase ability to perform everyday activities through increased physical function and self-efficacy in relation to be able to exercise and decreased pain-related beliefs such as fear of falling, catastrophizing thoughts and fear of movement.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Receives written and oral advice about physical Activity and the benefits of being physically active by one visits from a physiotherapist. Than will the participants receive Telephone reminder about following the advice once a week during intervention week 1-8 and 10.